NTLA Form 4: VP Michael Dube executed sell-to-cover of 1,871 RSU shares

Rhea-AI Filing Summary

Michael P. Dube, Vice President and Chief Accounting Officer of Intellia Therapeutics, Inc. (NTLA), reported a Form 4 disclosing a mandatory tax-withholding sale related to RSU vesting. On 10/01/2025 the reporting person had 1,871 shares sold (transaction code S(1)) at $17.38 per share to satisfy tax withholding obligations arising from RSU vesting. After the sale, the reporting person beneficially owned 55,266 shares. The Form 4 was signed by an attorney-in-fact and dated 10/03/2025. The filing describes the sale as non-volitional and linked solely to tax withholding.

Insights

Corporate Governance Analyst

Routine insider tax-withholding sale; shows compliance with reporting rules.

The Form 4 documents a mandatory sell-to-cover on 10/01/2025 for 1,871 shares at $17.38, which is explicitly described as non-volitional and tied to RSU vesting. This indicates the officer followed standard equity compensation procedures rather than executing a discretionary trade.

The timely filing and signature by an attorney-in-fact on 10/03/2025 reflect adherence to Section 16 reporting requirements, reducing governance or disclosure risk for the issuer.

Compensation & Equity Plan Specialist

Sell-to-cover reduces holdings modestly; no new compensation terms disclosed.

The sale satisfied tax withholding from vested RSUs; the report lacks any new grants, option exercises, or changes to the equity plan. The officer's post-transaction holding of 55,266 shares remains disclosed, providing clarity on retained insider exposure.

No information in the filing indicates additional planned sales or a 10b5-1 plan; the transaction is presented solely as a withholding mechanism.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dube Michael P

(Last) (First) (Middle)

C/O INTELLIA THERAPEUTICS, INC.

40 ERIE STREET; SUITE 130

(Street)

CAMBRIDGE MA 02139

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Intellia Therapeutics, Inc. [ NTLA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP, Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/01/2025		S(1)		1,871	D	$17.38	55,266	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on October 1, 2025, and does not represent a volitional trade by the Reporting Person.

	James Basta, attorney-in-fact	10/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Intellia (NTLA) insider Michael P. Dube report on Form 4?

The Form 4 reports a mandatory sell-to-cover of 1,871 shares at $17.38 on 10/01/2025 related to RSU tax withholding; post-transaction beneficial ownership is 55,266 shares.

Was the sale by the NTLA insider voluntary?

No. The filing explicitly describes the sale as a non-volitional, mandatory sell-to-cover to satisfy tax withholding upon RSU vesting.

When was the Form 4 for NTLA filed and who signed it?

The Form 4 shows the transaction date as 10/01/2025 and was signed by an attorney-in-fact, James Basta, with the signature dated 10/03/2025.

How many shares does Michael P. Dube own after the transaction?

After the reported sale, the reporting person beneficially owned 55,266 shares of Intellia Therapeutics common stock.

What was the sale price per share on the reported transaction?

The reported sale price was $17.38 per share for 1,871 shares.